Role of Bone Metabolic Marker Proteins in Calcified Lesions of Carotid Arteriosclerosis
Yu Hirokawa1,2, Hirotomo Ten3, Keisuke Onoda1,2 and Akira
1Department of Neurosurgery, International University of Health and Welfare, Narita Hospital, Chiba, Japan
2Graduate School of Medicine, International University of Health and Welfare, Chiba, Japan
3Department of Judo Physical Therapy, Faculty of Health Care, Teikyo Heisei
University, Tokyo, Japan
4Department of Neurosurgery, Teikyo University Chiba Medical Center, Chiba, Japan
*Corresponding Author: Akira Matsuno, Department of Neurosurgery, International University of Health and Welfare, Narita Hospital, Chiba, Japan.
October 25, 2022; Published: November 23, 2022
Vascular calcification is an important characteristic of atherosclerosis. According to histological analyses, bone formation tends to occur in heavily calcified carotid lesions devoid of ulceration and hemorrhage. Vascular calcification is not a simple degenerative and necrotic process associated with atherosclerosis but an active process similar to bone formation. Proteins involved in regulating skeletal bone formation are present in human atherosclerotic lesions. These proteins include osteoprotegerin and its ligand, bone sialoprotein, bone morphogenetic protein (BMP)-2 and BMP-4, osteocalcin, osteonectin, matrix Gla protein, and osteopontin. These molecules play important roles as active promotors for calcification or decalcification. These molecules are also important in inflammatory mechanisms in atherosclerosis and calcification.
Keywords:Vascular Calcification; Atherosclerosis; Bone Metabolic Marker Protein
- Hunt JL., et al. “Bone formation in carotid plaques: a clinicopathological study”. Stroke 33 (2002): 1214-
- Bini A., et al. “Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis”. Arteriosclerosis, Thrombosis, and Vascular Biology 19 (1999): 1852-1861.
- Dhore CR., et al. “Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques”. Arteriosclerosis, Thrombosis, and Vascular Biology 21 (2001): 1998-2003.
- Farzaneh-Far A., et al. “Vascular and valvar calcification: recent advances”. Heart 85 (2001): 13-17.
- Rittling SR., et al. “Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro”. The Journal of Bone and Mineral Research 13 (1998): 1101-1111.
- Asou Y., et al. “Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone”. Endocrinology 142 (2001): 1325-1332.
- Parhami F., et al. “High-density lipoprotein regulates calcification of vascular cells”. Circulation Research 91 (2002): 570-576.
- Shioi A., et al. “Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages”. Circulation Research 91 (2002): 9-16.
- Kakutani Y., et al. “Oncostatin M promotes osteoblastic differentiation of human vascular smooth muscle cells through JAK3-STAT3 pathway”. Journal of Cellular Biochemistry 116 (2015): 1325-1333.
- Aikawa E., et al. “Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo”. Circulation 116 (2007): 2841-2850.
- Dweck MR., et al. “Noninvasive molecular imaging of disease activity in atherosclerosis”. Circulation Research 119 (2016): 330-340.
- Denhardt DT and Guo X. “Osteopontin: a protein with diverse functions”. FASEB Journal 7 (1993): 1475-1482.
- Boskey AL., et al. “Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel”. Bone Mineral 22 (1993): 147-159.
- El-Abbadi M and Giachelli CM. “Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench”. Current Opinion in Nephrology and Hypertension 14 (2005): 519-
- Demer LL and Tintut Y. “Mineral exploration: search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award Lecture”. Arteriosclerosis, Thrombosis, and Vascular Biology 23 (2003): 1739-
- Giachelli CM., et al. “Regulation of vascular calcification: roles of phosphate and osteopontin”. Circulation Research 96 (2005): 717-
- Giachelli CM. “Vascular calcification: in vitro evidence for the role of inorganic phosphate”. Journal of the American Society of Nephrology 14 (2003): S300-
- Staines KA., et al. “The importance of the SIBLING family of proteins on skeletal mineralization and bone remodeling”. Journal of Endocrinology 214 (2012): 241-
- Tintut Y., et al. “Regulation of vascular calcification by osteoblast regulatory factors RANKL and osteoprotegerin”. Arteriosclerosis, Thrombosis, and Vascular Biology 95 (2004): 1046-
- Morony S., et al. “Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice”. Circulation 117 (2008): 411-
- Higgins CL., et al. “Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma”. The Protein Journal 34 (2015): 315-328.
- Giachelli CM., et al. “Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques”. Journal of Clinical Investigation 92 (1993): 1686-1696.
- Giachelli CM., et al. “Osteopontin expression in cardiovascular diseases”. Annals of the New York Academy of Sciences 760 (1995): 109-126.
- O'Brien ER., et al. “Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques”. Arteriosclerosis, Thrombosis 14 (1994): 1648-1656.
- Ikeda T., et al. “Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta”. Journal of Clinical Investigation 92(1993): 2814-2820.
- Hirota S., et al. “Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification”. The American Journal of Pathology 143 (1993):1003-1008.
- Fitzpatrick LA., et al. “Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis”. Journal of Clinical Investigation 94 (1994): 1597-1604.
- Takemoto M., et al. “Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis”. Arteriosclerosis, Thrombosis, and Vascular Biology 20(2000): 624-628.
- Ahmed S., et al. “Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells”. American Journal of Kidney Diseases 37 (2001): 1267-1276.
- O’Brien KD., et al. “Osteopontin is expressed in human aortic valvular lesions”. Circulation 92 (1995): 2163-2168.
- Shen M., et al. “Osteopontin is associated with bioprosthetic heart valve calcification in humans”. Comptes Rendus de l'Académie des Sciences - Series III 320 (1997): 49-57.
- Srivatsa SS., et al. “Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves”. Journal of Clinical Investigation 99 (1997): 996-1009.
- Canver CC., et al. “Association of osteopontin with calcification in human mitral valves”. The Journal of Cardiovascular Surgery (Torino) 41 (2000): 171-174.
- Giachelli CM., et al. “Osteopontin: potential roles in vascular function and dystrophic calcification”. Journal of Bone and Mineral Metabolism 15 (1997): 179-183.
- McKee MD and Nanci A. “Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair”. Microscopy Research and Technique 33(1996): 141-164.
- Wada T., et al. “Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin”. Circulation Research 84 (1999): 166-178.
- Cho HJ., et al. “Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification”. Current Atherosclerosis Reports 11 (2009): 206-213.